Provided by Tiger Fintech (Singapore) Pte. Ltd.

Enliven Treateutics

19.85
+0.91004.80%
Volume:216.04K
Turnover:4.24M
Market Cap:972.74M
PE:-10.50
High:20.16
Open:18.98
Low:18.57
Close:18.94
Loading ...

Company Profile

Company Name:
Enliven Treateutics
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
62
Office Location:
6200 Lookout Road,Boulder,Colorado,United States
Zip Code:
80301
Fax:
- -
Introduction:
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.

Directors

Name
Position
David M. Mott
Chairman of the Board
Rahul D. Ballal
President and Chief Executive Officer, Director
Barbara J. Dalton
Director
Carl Goldfischer
Director
David Bonita
Director
Edward R. Conner
Director
Laura Williams
Director
Mark Chin
Director
Sara Nayeem
Director

Shareholders

Name
Position
Rahul D. Ballal
President and Chief Executive Officer, Director
Michael P. Gray
Chief Financial Officer and Chief Operating Officer
Kenneth Attie
Senior Vice President and Chief Medical Officer